The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
01-Jun-22
$537 million
Target:
NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital
Acquiror:
Azorra Aviation
Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital
05-May-22
Undisclosed
Target:
Airtower Networks
Acquiror:
DIF Capital Partners
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
02-Nov-18
$NA
Target:
Pinnacle Midstream
Acquiror:
EagleClaw Midstream
Advised I Squared Capital on the contribution of Pinnacle Midstream, its Delaware Basin Midstream Company, to EagleClaw Midstream as part of the formation of a leading Delaware Basin Midstream Partnership with EagleClaw Midstream and Blackstone Energy Partners
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
29-Nov-17
$NA
Target:
Substantially all of the gas production and midstream assets of Energy Corporation of America
Acquiror:
Greylock Energy
Advised Energy Corporation of America, a natural gas producer focused on the Marcellus Shale, on the sale of substantially all its gas production and midstream assets to Greylock Energy, an affiliate of ArcLight Capital Partners
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
26-May-16
$500 million
Target:
Apex International Energy Management LLC
Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.